Giovanna Travi

Scopus Publications

Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation
Michele Bartoletti, Elena Rosselli Del Turco, Linda Bussini, Mical Paul, Eman Fares Sabik, Antonella Castagna, Marco Ripa, Marisa Z.R. Gomes, Stefano Di Bella, Marta Malosso, Alicia Beteta Lopez, Erica Franceschini, Alessandra Bandera, Viviana Barbieri, Alessandra Oliva, Patricia Munoz, Alessandra Mularoni, Elena Seminari, Paola Morelli, Carlo Tascini, Matthaios Papadimitriou-Olivgeris, Nicola Coppola, Francesco Cristini, Alessandro Russo, Matteo Bassetti, Giovanna Travi, Joaquin Lopez Contreras, Benedetta Varisco, Pierluigi Viale, Valeria Cento, Paolo Gaibani, Davide Fiore Bavaro, Maddalena Giannella, Chiara Oltolini, Paolo Scarpellini, André Monteiro de Barros Titonelli, Isabel Ribeiro Gomes de Queiroz Crespo, Verena Zerbato, Martina Spaziante, Martina Del Monte, Antonio Muscatello, Maricela Vario Minerio, Ivan Adan, Daniele Giacobbe, Margherita Macera, Marco Merli, Iris Artesero Rosa, Alba Ribera, Virginia Pomar, Alice Medaglia, Giovanna Russelli, Ivan Gentile, Riccardo Scotto, Alberto Maraolo, Francesco Romeo, Oana Cristea
Clinical Microbiology and Infection, 2026
Clinical Spectrum of Children With Parvovirus B19–Associated Acute Myocarditis
Enrico Ammirati, Giacomo Veronese, Francesca Raimondi, Giuseppe Alberto Annoni, Domenico Sirico, Francesco Bianco, Alessio Franceschini, Gessica Ingrasciotta, Giovanni Meliota, Guglielmo Capponi, Isabella Pellicioli, Gaia Biancamaria Chiesa, Carlo Beretta, Giada Colombo, Giovanni Di Salvo, Sandra Nonini, Francesca Aresta, Luca Ragni, Tammam Hasan, Maurizio Brighenti, Giovanna Travi, Olivia Leoni, Paul Stefan Vrabie, Michele Ercolanoni, Giuseppe Limongelli, Emanuele Monda, Maria Giovanna Russo, Alessandra Corato, Elena Reffo, Valentina Bucciarelli, Sergio Filippelli, Susanna Breviario, Carlo Pace Napoleone, Ugo Vairo, Maristella Lombardi, Nadia Assanta, Pietro Marchese, Paolo Ferrero, Flavio Luciano Ribichini, Andrea Garascia, Michele Giovanni Mondino, Antonio Amodeo, Rachele Adorisio, Ezio Bonanomi
Circulation, 2026
BACKGROUND: Parvovirus B19 is a DNA virus transmitted via respiratory droplets, commonly causing erythema infectiosum in children but also implicated in acute myocarditis. In 2024, an outbreak of parvovirus B19 infections was reported across Europe and the United States. Despite growing awareness, data on the clinical features and outcomes of children with parvovirus B19–associated acute myocarditis remain limited. METHODS: This multicenter retrospective observational study reviewed medical records of pediatric patients (<18 years of age) admitted with acute myocarditis to 11 Italian tertiary pediatric cardiac centers between January 1, 2022, and October 31, 2024. Of 217 cases, 66 had confirmed parvovirus B19 DNA in plasma (PVB19 + ), whereas 82 with negative parvovirus B19 testing served as a comparator group (PVB19 − ). Population-based incidence trends of pediatric myocarditis were also evaluated in the Lombardy region from 2004 through 2024. RESULTS: Among PVB19 + acute myocarditis cases, 58 of 66 (87.9%) were admitted in 2024. The median age was 32 months, with 51 of 66 (77.2%) ≤7 years of age, and 36 of 66 (54.5%) were boys. Median plasma viral load was 34 411 copies/mL, whereas only 30 of 56 (53.6%) had immunoglobulin M (IgM) positivity. Among 26 of 66 (39.4%) with available histology, 23 (88.4%) had lymphocytic myocarditis, and parvovirus B19 DNA was identified in 84.0% of myocardial specimens. Among 25 of 65 (38.4%) who underwent genetic testing, none had pathogenic or likely pathogenic variants. Overall, 13 of 66 (19.7%) died, underwent heart transplantation, or received a durable left ventricular assist device (in total, there were 6 deaths, 5 durable left ventricular assist devices, and 5 transplantations) compared with 1 of 82 (1.2%) among PVB19 − acute myocarditis (one patient who received a durable left ventricular assist device and later underwent transplantation; P <0.001). A marked increase in regional and institutional myocarditis incidence in pediatric acute myocarditis was observed in 2024, predominantly in children ≤7 years of age, driven by PVB19 + cases. CONCLUSIONS: During the 2024 parvovirus B19 outbreak, pediatric PVB19 + acute myocarditis cases surged in Italy and were associated with severe outcomes. A high index of suspicion is required for diagnosis, and early virological testing is essential to guide management and potentially improve outcomes.
Patterns and Correlates of Initiation of Long-Acting Injectable Cabotegravir for Preexposure Prophylaxis: A Case-Control Analysis
Roberto Rossotti, Gabriele Cavazza, Enrico Caruso, Chiara Baiguera, Elisa Di Gennaro, Nicholas Brian Bana, Giulia Burastero, Leonardo Francesco Rezzonico, Leonardo Luzi, Giovanna Travi, Marco Merli, Massimo Puoti
Sexually Transmitted Diseases, 2026
We conducted a case-control analysis to evaluate the determinants for initiating long-acting injectable cabotegravir (LACAB) as preexposure prophylaxis (PrEP) in a real-world setting with limited drug access. Individuals selected for LACAB experienced more side effects from oral PrEP, riskier sexual behavior, longer prior PrEP use, and a significantly higher incidence of STIs during follow-up. Despite this, LACAB was well tolerated, and discontinuation rates were low. Our findings support prioritizing LACAB for individuals most exposed to HIV and with low adherence to oral regimens, especially in contexts where logistical or economic constraints limit universal access to PrEP.
Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteraemia: external validation with decision curve analysis
Benedetta Varisco, Daniele Piovani, Elena Rosselli Del Turco, Linda Bussini, Mical Paul, Eman Fares Sabik, Antonella Castagna, Marco Ripa, Marisa Z.R. Gomes, Stefano Di Bella, Verena Zerbato, Alicia Beteta Lopez, Erica Franceschini, Alessandra Bandera, Alessandra Oliva, Francesca Gavaruzzi, Patricia Muñoz, Alessandra Mularoni, Elena Seminari, Paola Morelli, Daria Pocaterra, Carlo Tascini, Matthaios Papadimitriou-Olivgeris, Nicola Coppola, Francesco Cristini, Alessandro Russo, Matteo Bassetti, Giovanna Travi, Joaquin Lopez-Contreras, Pierluigi Viale, Valeria Cento, Lucia Diella, Davide Fiore Bavaro, Paolo Gaibani, Maddalena Giannella, Michele Bartoletti, Ivan Adan, Iris Artesero Sosa, Oana Cristea, Martina Del Monte, Daniele Giacobbe, Marcos Junqueira do Lago, Margherita Macera, Alberto Maraolo, Alice Medaglia, Marco Merli, Maricela Vario Minerio, Antonio Muscatello, Chiara Oltolini, Virginia Pomar, Giovanna Russelli, Robson de Souza Leão, Paolo Scarpellini, Riccardo Scotto, Roberta Ferreira Gomes Saldanha-Gama, Martina Spaziante
Clinical Microbiology and Infection, 2026
Use of a molecular syndromic panel for the etiological diagnosis of ventilator-associated bacterial pneumonia: impact on clinical outcomes and antibiotic use from a multicenter, prospective study
Daniele Roberto Giacobbe, Greta Cattardico, Claudia Bartalucci, Vincenzo Di Pilato, Marco Muccio, Alessandro Limongelli, Alessio Signori, Alessandra Bandera, Bruno Cacopardo, Edoardo Campanella, Alessandro Caroli, Annamaria Cattelan, Marta Colaneri, Andrea Cortegiani, Laura Curci, Gennaro De Pascale, Giuseppe Vittorio De Socio, Filippo Del Puente, Antonino Di Fede, Chiara Fanelli, Nicholas Geremia, Maddalena Giannella, Giacomo Grasselli, Chiara Maci, Ivana Maida, Davide Mangioni, Andrea Marino, Maria Mazzitelli, Maria Chiara Meloni, Marco Merli, Elena Momesso, Chiara Oltolini, Carlo Pallotto, Sandro Panese, Matteo Passerini, Emanuele Pontali, Daniele Riccucci, Matteo Rinaldi, Marco Ripa, Vincenzo Scaglione, Francesco Saverio Serino, Vincenzo Spagnuolo, Giulia Spurio, Stefania Tigano, Carlo Torti, Giovanna Travi, Laura Magnasco, Federica Portunato, Federica Briano, Malgorzata Mikulska, Lorenzo Ball, Chiara Robba, Nicolò Patroniti, Denise Battaglini, Mauro Giacomini, Gian Maria Rossolini, Maurizio Sanguinetti, Paola Morici, Anna Marchese, Antonio Vena, Matteo Bassetti, , Ylenia Murgia, Gabriele Di Meco, Alice Cappello, Sabrina Guastavino, Cristina Campi, Michele Piana, Sara Mora, Nicola Rosso, Antonio Di Biagio, Giulia Viglietti, Annaflavia Lamarina, Luca De Paola, Stefano Antola, Selene Gallone, Federica Cosentino, Chiara Gullotta, Marco Piscaglia, Federico D’Amico, Serena Sassi, Elena Simoncini, Giacomo Gonnelli, Anna Gidari, Lisa Malincarne, Nicoletta Bobbio, Andrea Parisini, Annalisa Garlaschelli, Sara Grignolo, Fabiola Cammarota, Paola Del Giacomo, Brunella Posteraro, Andrea Lombardi, Antonio Muscatello, Carlo Peri, Mara Tomasello, Nicoletta Boffa, Elena Potenza, Antonella Castagna, Roberta Monardo, Giulia Catalisano, Michela Di Maio, Antonino Giarratano, Mariachiara Ippolito, Pierluigi Viale
Critical Care, 2025
Ventilator-associated bacterial pneumonia (VABP) is a common infection in critically ill patients in intensive care units (ICU), with attributable mortality of up to 13%, and its etiological diagnosis remains challenging. We conducted a multicenter, prospective, observational study within the MULTI-SITA platform to assess the impact on relevant clinical and antimicrobial stewardship outcomes of the use of a molecular syndromic panel (BIOFIRE® FILMARRAY® Pneumonia plus), in addition to a standard approach based on culture. The primary outcome measure was 30-day mortality from VABP onset. Overall, 237 patients with VABP were included in the study. In multivariable analysis, SOFA score (hazard ratio [HR] 1.13, 95% confidence interval [CI] 1.04–1.22, p = 0.003), previous isolation of carbapenem-resistant Pseudomonas aeruginosa (HR 3.02, 95% CI 1.25–7.32, p = 0.015), and solid neoplasm (HR 2.15, 95% CI 1.12–4.14, p = 0.022) were associated with increased mortality, while no association was registered for the molecular syndromic panel performed (HR 1.07, 95% CI 0.59–1.93, p = 0.825). In secondary analyses, use of the molecular syndromic panel resulted in more events of either de-escalation or initiation of appropriate antibiotic therapy at day 1 from VABP onset in comparison with a standard approach based on culture only (41.3% vs. 27.8%, p = 0.041). The use of a molecular syndromic panel in patients with VABP was able to impact antibiotic decisions, without an unfavorable effect on mortality. Further study is necessary to assess the long-term effects in terms of antimicrobial stewardship of molecular syndromic panels-based antibiotic treatment decisions.
Cefiderocol therapy among immunocompromised adult patients: a descriptive analysis from a prospective, multicentre cohort study
Andrea Lombardi, Daniele Roberto Giacobbe, Davide Mangioni, Bianca Mariani, Antonio Muscatello, Marco Muccio, Chiara Aldieri, Federica Briano, Bruno Cacopardo, Alessandra Calabresi, Federico Capra Marzani, Anna Carretta, Annamaria Cattelan, Luca Ceccarelli, Giovanni Cenderello, Silvia Corcione, Andrea Cortegiani, Rosario Cultrera, Francesco Giuseppe De Rosa, Valerio Del Bono, Filippo Del Puente, Chiara Fanelli, Fiorenza Fava, Daniela Francisci, Nicholas Geremia, Lucia Graziani, Angela Raffaella Losito, Ivana Maida, Andrea Marino, Maria Mazzitelli, Marco Merli, Roberta Monardo, Alessandra Mularoni, Chiara Oltolini, Carlo Pallotto, Emanuele Pontali, Francesca Raffaelli, Matteo Rinaldi, Marco Ripa, Teresa Antonia Santantonio, Francesco Saverio Serino, Michele Spinicci, Carlo Torti, Enrico Maria Trecarichi, Mario Tumbarello, Malgorzata Mikulska, Antonio Vena, Alessandra Bandera, Matteo Bassetti, , Cristina Marelli, Vincenzo Di Pilato, Alessio Signori, Laura Labate, Chiara Russo Artimagnella, Mauro Giacomini, Anna Marchese, Ylenia Murgia, Gabriele Di Meco, Alice Cappello, Sabrina Guastavino, Cristina Campi, Michele Piana, Sara Mora, Nicola Rosso, Antonio Di Biagio, Giulia Viglietti, Iole Brunetti, Chiara Robba, Lorenzo Ball, Denise Battaglini, Federica Portunato, Maddalena Giannella, Pierluigi Viale, Giulia Viero, Cecilia Azzarà, Paola Saltini, Alessandro Bartoloni, Benedetta Casciato, Chiara Grillo, Donatella Concetta Cibelli, Silvia Boni, Marcello Feasi, Paola Del Giacomo, Gianmaria Baldin, Federico D’Amico, Giovanna Travi, Teresa Fasciana, Giulia Catalisano, Antonino Giarratano, Elena Baranello, Margherita Albagini, Chiara Maci, Antonella Castagna, Cecilia Grosso, Nour Shbaklo, Elena Momesso, Nicoletta Boffa, Elena Potenza, Vincenzo Scaglione, Daniele Mengato, Alessandro Russo, Ludovica Corsello, Francesca Serapide, Monica Rizzo, Erika Asperges, Francesco Truffelli, Margherita Sambo, Gabriele Giuliano, Francesco Fele, Chiara Gullotta, Edoardo Campanella, Maria Chiara Meloni, Sabrina Boraso, Sandro Panese, Aurora Bonazza, Kristian Scolz, Erika Coppo, Marco Berruti
BMC Infectious Diseases, 2025
The global rise in infections due to multidrug-resistant Gram-negative bacteria (MDRGNB) infections has disproportionately impacted immunocompromised (IC) hosts. Cefiderocol, a novel siderophore cephalosporin, exhibits potent activity against MDRGNB, but limited data exist on its use in IC patients. This study aimed to describe cefiderocol use in IC patients. Patients and therapy characteristics were descriptively reported, and outcomes were compared between IC and non-IC patients. Cox regression models were used to identify factors associated with mortality. Among 185 patients, 84 (45.4%) were IC. Similar descriptive rates were observed in IC and non-IC groups regarding indications for cefiderocol use, choice of monotherapy versus combination therapy, or empirical versus targeted treatment. The 28-day clinical cure rates were similar across patients receiving targeted cefiderocol therapy for infection due to Pseudomonas aeruginosa (81%, 17/21), Enterobacterales (77.3%, 17/22) and Acinetobacter baumannii (42%, 21/50). Thirty-day mortality was comparable between IC and non-IC patients (40.8%, 95% confidence interval [CI] 27.9–56.8 vs 33.3%, 95% CI 22.9–46.9; p = 0.5430). In multivariable analysis IC status was not associated with higher mortality. Cefiderocol use in IC patients resulted in clinical outcomes comparable to non-IC patients when treating MDRGNB infections. IC status was not associated with an increased mortality, emphasising the importance of effective antimicrobial therapy. Further investigation is needed to clarify the relative impact of the administered treatment vs. the patients’ clinical condition in influencing the prognosis of Acinetobacter baumannii infections.
Use of isavuconazole in critically ill patients in intensive care units: A prospective, observational, multicentre, cohort study
Daniele Roberto Giacobbe, Claudia Bartalucci, Martina Bavastro, Riccardo Schiavoni, Vincenzo Di Pilato, Marco Muccio, Alessio Signori, Chiara Aldieri, Jacopo Angelini, Erika Asperges, Elisabetta Blasi Vacca, Nicoletta Boffa, Enrica Bono, Bruno Cacopardo, Alessandra Calabresi, Martina Casarini, Annamaria Cattelan, Silvia Corcione, Federica Cosentino, Gennaro De Pascale, Francesco Giuseppe De Rosa, Valerio Del Bono, Filippo Del Puente, Chiara Fanelli, Fiorenza Fava, Erica Franceschini, Nicholas Geremia, Maddalena Giannella, Simone Giuliano, Ivana Maida, Andrea Marino, Maria Mazzitelli, Maria Chiara Meloni, Marco Merli, Marianna Meschiari, Chiara Moreal, Chiara Oltolini, Rita Pallone, Sandro Panese, Emanuele Pontali, Martina Ricciardetto, Matteo Rinaldi, Alessandro Russo, Maurizio Sanguinetti, Vincenzo Scaglione, Francesca Serapide, Francesco Saverio Serino, Nour Shbaklo, Carlo Torti, Giovanna Travi, Laura Magnasco, Federica Portunato, Federica Briano, Malgorzata Mikulska, Lorenzo Ball, Chiara Robba, Nicolò Patroniti, Denise Battaglini, Mauro Giacomini, Erika Coppo, Anna Marchese, Antonio Vena, Matteo Bassetti, , Ylenia Murgia, Gabriele Di Meco, Alice Cappello, Sabrina Guastavino, Cristina Campi, Michele Piana, Sara Mora, Nicola Rosso, Antonio Di Biagio, Giulia Viglietti, Annaflavia Lamarina, Stefano Antola, Selene Gallone, Pierluigi Viale, Edoardo Antonio Campanella, Alessandro Franzò, Chiara Gullotta, Davide Costarella, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Silvia Boni, Stefania Tigano, Maddalena Albertini, Davide Chemello, Antonella Santoro, Daniele Mengato, Martina Munari, Paolo Navalesi, Ivo Tiberio, Ilaria De Benedetto, Tommaso Lupia, Simone Mornese Pinna, Sara Ferin, Sarah Flammini, Luca Martini, Luca Montanari, Stefania Musso, Federico D’amico, Serena Sassi, Elena Simoncini, Elena Momesso, Fabiola Cammarota, Alessandro Caroli, Daniel Livanu, Angela Raffaella Losito
Jac Antimicrobial Resistance, 2025
Objectives In this multicentre, prospective study, we aimed to describe the use of isavuconazole in critically ill adult patients in ICU, in terms of patient characteristics, infection characteristics and outcomes. Methods Prospective, observational study of ICU patients treated with isavuconazole from January 2023 to 30 April 2025 in 17 centres (ISA-SITA study within the MULTI-SITA project). Results A total of 177 ICU patients treated with isavuconazole were included in the study. Most patients showed at least one European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) or FUNgal Diseases in adult patients in Intensive Care Unit (FUNDICU) host factor (141/177, 79.7%). Overall, 82/177 patients (46.3%) had either proven or probable invasive mould disease (6 and 76, respectively, mostly invasive pulmonary aspergillosis). In patients with proven or probable disease, 30-day mortality was 44.0%, and 90-day mortality was 62.2%. In multivariable analyses, SOFA score (HR 1.14 per one point increase, 95% CI 1.03–1.26, P = 0.010) and concomitant bacterial pneumonia (HR 2.32, 95% CI 1.17–4.59, P = 0.016) were associated with 30-day mortality, whereas prior hospitalization (HR 2.26, 95% CI 1.19–4.27, P = 0.013) and SOFA score (HR 1.17 per one point increase, 95% CI 1.07–1.28, P &lt; 0.001) were associated with 90-day mortality. Conclusions Diverse patterns of isavuconazole use were observed in a large cohort of critically ill adult patients, and the drug was well tolerated. Mortality was lower than many previous estimates in critically ill patients and could serve as a basis for future standardized comparisons.
Outbreak of Vancomycin-Resistant Enterococcus in a NICU: Insights into Molecular Detection and Infection Control †
Francesco Peracchi, Giovanna Travi, Alice Proto, Elena Nicolini, Andrea Busni, Luca Mezzadri, Livia Tartaglione, Alessandra Bielli, Elisa Matarazzo, Giorgia Casalicchio, Cecilia Del Curto, Roberto Rossotti, Marco Merli, Chiara Vismara, Fulvio Crippa, Stefano Martinelli, Massimo Puoti
Microorganisms, 2025
Vancomycin-resistant enterococci (VRE) are a major cause of healthcare-associated infections (HAIs). However, the clinical significance of VRE colonization and the subsequent risk of VRE infection in hospitalized patients are not fully established. Prolonged hospital stays have been observed in neonates colonized by VRE. The mortality rate in pediatric patients with VRE infections ranges from 0% to 42% in both endemic and outbreak settings, often occurring in VRE-colonized neonates. Host and bacterial factors associated with a worse outcome are not fully understood yet. We describe an outbreak of VRE colonization in 21 newborns admitted to our neonatal intensive care unit in January 2024. Microbiological analyses on rectal swabs were performed using molecular testing and culture. Results: In January, VRE was first detected in the urine culture of a 3-week-old patient, followed by a subsequent positive rectal swab result. In accordance with our infection control policy, all the NICU patients were tested, leading to the identification of another 12 colonized patients. The implementation of molecular testing led to rapid VRE identification and the subsequent isolation of colonized neonates, which promptly contained the outbreak. The median time from NICU admission to colonization was 34 (6–37) days. Only one patient developed a CVC-related bloodstream infection, which was successfully treated with linezolid and CVC removal. No VRE-related deaths occurred, even among three patients who underwent abdominal surgery (one gastroschisis, one incarcerated abdominal hernia, and one umbilical hernia) and one patient with necrotizing enterocolitis. Our data show a low infection rate (4%) among VRE-colonized patients (4%) during a NICU outbreak. The rapid identification of multidrug-resistant genes by molecular testing may be implemented in specific settings to enable timely patient identification, adopt infection control measures, and administer appropriate antimicrobial therapy.
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection
Giovanna Travi, Francesco Peracchi, Marco Merli, Emanuele Ravano, Anna Frustaci, Marina Deodato, Diana Fanti, Alice Nava, Valeriana Colombo, Nicholas Brian Bana, Carlotta Rogati, Alessandro Raimondi, Cristina Moioli, Anna Maria Pazzi, Marta Vecchi, Davide Motta, Roberto Rossotti, Chiara Oltolini, Fulvio Crippa, Enrico Minetti, Chiara Vismara, Roberto Cairoli, Massimo Puoti
Infectious Disease Reports, 2025
Background: Immunosuppressed patients still exhibit a high mortality rate due to SARS-CoV-2 infection, up to 21%. Persistent viral load replication and protracted viral symptoms result in a high risk of developing pneumonia, a potential risk of antiviral resistance, and a subsequent delay of onco-hematological treatments. Methods: Hematological patients and kidney transplant patients with SARS-CoV-2 infection, treated at GOM Niguarda Hospital (Milan) with combined antiviral therapy (remdesivir plus nirmatrelvir/ritonavir at standard doses) between November 2022 and March 2024, were retrospectively reviewed. Results: Thirty-four patients were analyzed. Twenty-four (71%) patients had pneumonia. The median duration of SARS-CoV-2 positivity before antiviral treatment was 40 (10–34) days. The median treatment duration was 11 (10–10) days. All patients went through clinical resolution. Thirteen patients were exposed to a new immune-chemotherapy cycle early after antiviral treatment (median 13, IQR 6–12 days), while five resumed a standard immunosuppressive regimen immediately after viral clearance. No relapse or recurrence of symptoms was reported for up to 226 (106–318) days of follow-up. Antiviral therapy was well tolerated, and no adverse events were observed. The 30-day overall survival was 94%, while the 90-day survival was 88%. No patient died of SARS-CoV-2 infection. Conclusions: The administration of nirmatrelvir/ritonavir and remdesivir lead to the complete resolution of SARS-CoV-2 pneumonia with no side effects in this cohort. The combination of these two antivirals may be a safe option in immunosuppressed population at risk of severe complications and prolonged SARS-CoV-2 infection in order to treat severe clinical presentation and to avoid viral recurrence after chemotherapy.
The Impact of Prior COVID-19 on Noninfectious Endothelial Complications Following Allogeneic Hematopoietic Stem Cell Transplantation
Chiara Oltolini, Giovanna Travi, Malgorzata Mikulska
Clinical Infectious Diseases, 2025
Journal Article Accepted manuscript The impact of prior COVID-19 on non-infectious endothelial complications following allogeneic hematopoietic stem cell transplantation Get access Chiara Oltolini, Chiara Oltolini ASST Grande Ospedale Metropolitano Niguarda, Infectious Diseases Unit, Milan, Italy Corresponding author: Chiara, Oltolini, ASST Grande Ospedale Metropolitano Niguarda, Infectious Diseases Unit, Milan, Italy, e-mail: chiara.oltolini@ospedaleniguarda.it Search for other works by this author on: Oxford Academic PubMed Google Scholar Giovanna Travi, Giovanna Travi ASST Grande Ospedale Metropolitano Niguarda, Infectious Diseases Unit, Milan, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Malgorzata Mikulska Malgorzata Mikulska San Martino Hospital, Infectious Diseases Unit, Genoa, Italy https://orcid.org/0000-0002-5535-4602 Search for other works by this author on: Oxford Academic PubMed Google Scholar Clinical Infectious Diseases, ciae307, https://doi.org/10.1093/cid/ciae307 Published: 05 June 2024 Article history Received: 21 March 2024 Revision received: 04 April 2024 Accepted: 30 May 2024 Published: 05 June 2024
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study
Daniele Roberto Giacobbe, Laura Labate, Chiara Russo Artimagnella, Cristina Marelli, Alessio Signori, Vincenzo Di Pilato, Chiara Aldieri, Alessandra Bandera, Federica Briano, Bruno Cacopardo, Alessandra Calabresi, Federico Capra Marzani, Anna Carretta, Annamaria Cattelan, Luca Ceccarelli, Giovanni Cenderello, Silvia Corcione, Andrea Cortegiani, Rosario Cultrera, Francesco Giuseppe De Rosa, Valerio Del Bono, Filippo Del Puente, Chiara Fanelli, Fiorenza Fava, Daniela Francisci, Nicholas Geremia, Lucia Graziani, Andrea Lombardi, Angela Raffaella Losito, Ivana Maida, Andrea Marino, Maria Mazzitelli, Marco Merli, Roberta Monardo, Alessandra Mularoni, Chiara Oltolini, Carlo Pallotto, Emanuele Pontali, Francesca Raffaelli, Matteo Rinaldi, Marco Ripa, Teresa Antonia Santantonio, Francesco Saverio Serino, Michele Spinicci, Carlo Torti, Enrico Maria Trecarichi, Mario Tumbarello, Malgorzata Mikulska, Mauro Giacomini, Anna Marchese, Antonio Vena, Matteo Bassetti, , Ylenia Murgia, Gabriele Di Meco, Alice Cappello, Sabrina Guastavino, Cristina Campi, Michele Piana, Sara Mora, Nicola Rosso, Antonio Di Biagio, Giulia Viglietti, Iole Brunetti, Chiara Robba, Lorenzo Ball, Denise Battaglini, Federica Portunato, Maddalena Giannella, Pierluigi Viale, Giulia Viero, Cecilia Azzarà, Alessandro Bartoloni, Benedetta Casciato, Chiara Grillo, Donatella Cibelli, Silvia Boni, Marcello Feasi, Paola Del Giacomo, Gianmaria Baldin, Federico D’Amico, Giovanna Travi, Teresa Fasciana, Giulia Catalisano, Antonino Giarratano, Elena Baranello, Margherita Albagini, Chiara Maci, Antonella Castagna, Cecilia Grosso, Nour Shbaklo, Elena Momesso, Nicoletta Boffa, Elena Potenza, Vincenzo Scaglione, Daniele Mengato, Alessandro Russo, Ludovica Corsello, Francesca Serapide, Monica Rizzo, Erika Asperges, Francesco Truffelli, Margherita Sambo, Gabriele Giuliano, Francesco Fele, Chiara Gullotta, Edoardo Campanella, Maria Chiara Meloni, Sabrina Boraso, Sandro Panese, Aurora Bonazza, Kristian Scolz, Erika Coppo, Marco Berruti
Infectious Diseases and Therapy, 2024
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort
Alessandro Soria, Francesca Graziano, Giulia Ghilardi, Giuseppe Lapadula, Daniela Dalla Gasperina, Simone Vasilij Benatti, Eugenia Quiros-Roldan, Maurizio Milesi, Francesca Bai, Marco Merli, Davide Minisci, Marco Franzetti, Erika Asperges, Filippo Chiabrando, Daria Pocaterra, Alessandro Pandolfo, Fabio Zanini, Domenico Lombardi, Anna Cappelletti, Alban Rugova, Maria Lucia Borghesi, Nicola Squillace, Luigi Pusterla, Stefania Piconi, Paola Morelli, Patrizia Rovere Querini, Raffaele Bruno, Stefano Rusconi, Salvatore Casari, Alessandra Bandera, Fabio Franzetti, Giovanna Travi, Antonella D'Arminio Monforte, Giulia Marchetti, Angelo Pan, Francesco Castelli, Marco Rizzi, Francesco Dentali, Maria Mallardo, Emanuela Rossi, Maria Grazia Valsecchi, Stefania Galimberti, Paolo Bonfanti
Heliyon, 2024
Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak
Giovanna Travi, Francesco Peracchi, Marco Merli, Noemi Lo Re, Elisa Matarazzo, Livia Tartaglione, Alessandra Bielli, Giorgia Casalicchio, Fulvio Crippa, Chiara S. Vismara, Massimo Puoti
Antibiotics, 2024
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management
Gabriele Cavazza, Cristina Motto, Caroline Regna-Gladin, Giovanna Travi, Elisa Di Gennaro, Francesco Peracchi, Bianca Monti, Nicolò Corti, Rosa Greco, Periana Minga, Marta Riva, Sara Rimoldi, Marta Vecchi, Carlotta Rogati, Davide Motta, Annamaria Pazzi, Chiara Vismara, Laura Bandiera, Fulvio Crippa, Valentina Mancini, Maria Sessa, Chiara Oltolini, Roberto Cairoli, Massimo Puoti
Antibiotics, 2024
Meropenem–Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature
Leonardo Francesco Rezzonico, Francesco Peracchi, Marta Vecchi, Gabriele Bassi, Marco Merli, Nicholas Brian Bana, Giovanna Travi, Fulvio Crippa, Massimo Puoti
Antibiotics, 2024
A case of chronic bacterial prostatitis due to Mycoplasma genitalium
Roberto Rossotti, Giovanna Travi, Nicholas Brian Bana, Carloandrea Orcese, Massimo Puoti
Sexually Transmitted Infections, 2023
Effectiveness and Safety of Remdesivir in Treating Hospitalised Patients with COVID-19: A Propensity Score Analysis of Real-Life Data from a Monocentric Observational Study in Times of Health Emergency
Nicola Ughi, Davide Paolo Bernasconi, Francesca Del Gaudio, Armanda Dicuonzo, Alessandro Maloberti, Cristina Giannattasio, Paolo Tarsia, Giovanna Travi, Francesco Scaglione, Fabrizio Colombo, Michaela Bertuzzi, Antonella Adinolfi, Maria Grazia Valsecchi, Claudio Rossetti, Oscar Massimiliano Epis, and
Clinical Drug Investigation, 2023
The effect of antithrombotic treatment on mortality in patients with acute infection: A meta-analysis of randomized clinical trials
Gianluca Gazzaniga, Giovanni Amedeo Tavecchia, Francesca Bravi, Francesca Scavelli, Giovanna Travi, Gianluca Campo, Christophe Vandenbriele, Tobias Tritschler, Jonathan A.C. Sterne, Srinivas Murthy, Nuccia Morici
International Journal of Cardiology, 2023
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection
F. Peracchi, M. Merli, C. Rogati, E. Ravano, M. Puoti, R. Cairoli, G. Travi
British Journal of Haematology, 2023
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi
Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, Chiara Borella, Gianluigi Reda, Marina Motta, Marina Deodato, Elisa Bossi, Veronica Mattiello, Maria Beatrice Ferrari, Giulia Cotilli, Carlo Gambacorti-Passerini, Roberto Cairoli, Massimo Puoti, Alessandra Tedeschi
Hemasphere, 2023
Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation
Roberto Rossotti, Marco Merli, Chiara Mazzarelli, Riccardo Maria De Carlis, Giovanna Travi, Marta Vecchi, Raffaella Viganò, Andrea Lauterio, Alessandro Raimondi, Luca Saverio Belli, Luciano Gregorio De Carlis, Massimo Puoti
Digestive and Liver Disease, 2023
Immune-Suppression Modulation in Solid Organ Transplant Recipients Admitted for COVID-19
Francesco Peracchi, Giovanna Travi, Marco Merli, Roberto Rossotti, Fulvio Crippa, Massimo Puoti
Obm Transplantation, 2023
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study
Luna Colagrossi, Maria Antonello, Silvia Renica, Marco Merli, Elisa Matarazzo, Giovanna Travi, Marta Vecchi, Jacopo Colombo, Antonio Muscatello, Giacomo Grasselli, Silvia Nerini Molteni, Vittorio Scaravilli, Emanuele Cattaneo, Diana Fanti, Chiara Vismara, Alessandra Bandera, Andrea Gori, Massimo Puoti, Valeria Cento, Claudia Alteri, Carlo Federico Perno
BMC Infectious Diseases, 2021
Characteristics and clinical implications of carbapenemase-producing klebsiella pneumoniae colonization and infection, Italy
Marianna Rossi, Liliane Chatenoud, Floriana Gona, Isabella Sala, Giovanni Nattino, Alessia D'Antonio, Daniele Castelli, Teresa Itri, Paola Morelli, Sara Bigoni, Chiara Aldieri, Roberto Martegani, Paolo A. Grossi, Cecilia Del Curto, Stefania Piconi, Sara G. Rimoldi, Paola Brambilla, Paolo Bonfanti, Evelyn Van Hauwermeiren, Massimo Puoti, Gianni Gattuso, Chiara Cerri, Mario C. Raviglione, Daniela M. Cirillo, Alessandra Bandera, Andrea Gori, and
Emerging Infectious Diseases, 2021
Neurological manifestations in patients hospitalized with COVID-19: A retrospective analysis from a large cohort in Northern Italy
Giovanna Travi, Roberto Rossotti, Marco Merli, Federico D’Amico, Stefania Chiappetta, Giuditta Giussani, Adelaide Panariello, Matteo Corradin, Marta Vecchi, Alessandro Raimondi, Chiara Baiguera, Benedetta Nocita, Oscar Massimiliano Epis, Paolo Tarsia, Filippo Galbiati, Fabrizio Colombo, Roberto Fumagalli, Francesco Scaglione, Mauro Moreno, Mauro Emilio Percudani, Elio Clemente Agostoni, Massimo Puoti, and
European Journal of Neuroscience, 2021
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients
Marco Merli, Luisa Pasulo, Giovanni Perricone, Giovanna Travi, Roberto Rossotti, Valeriana Giuseppina Colombo, Riccardo De Carlis, Stefania Chiappetta, Maria Cristina Moioli, Enrico Minetti, Maria Frigerio, Luciano Gregorio De Carlis, Luca Belli, Stefano Fagiuoli, Massimo Puoti
Journal of Infection, 2021
Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection
Marco Merli, Claudia Alteri, Luna Colagrossi, Giovanni Perricone, Stefania Chiappetta, Giovanna Travi, Daniela Campisi, Maria Teresa Pugliano, Marta Vecchi, Carloandrea Orcese, Silvano Rossini, Luciano De Carlis, Chiara Vismara, Luca Belli, Carlo Federico Perno, Massimo Puoti
Transplantation, 2021
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
Marco Merli, Giovanni Perricone, Andrea Lauterio, Manlio Prosperi, Giovanna Travi, Elena Roselli, Laura Petrò, Luciano De Carlis, Luca Belli, Massimo Puoti
Liver Transplantation, 2020
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy
Valeria Cento, Claudia Alteri, Marco Merli, Federica Di Ruscio, Livia Tartaglione, Roberto Rossotti, Giovanna Travi, Marta Vecchi, Alessandro Raimondi, Alice Nava, Luna Colagrossi, Roberto Fumagalli, Nicola Ughi, Oscar Massimiliano Epis, Diana Fanti, Andrea Beretta, Filippo Galbiati, Francesco Scaglione, Chiara Vismara, Massimo Puoti, Daniela Campisi, Carlo Federico Perno
Plos One, 2020
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis
Roberto Rossotti, Giovanna Travi, Nicola Ughi, Matteo Corradin, Chiara Baiguera, Roberto Fumagalli, Maurizio Bottiroli, Michele Mondino, Marco Merli, Andrea Bellone, Andriano Basile, Ruggero Ruggeri, Fabrizio Colombo, Mauro Moreno, Stefano Pastori, Carlo Federico Perno, Paolo Tarsia, Oscar Massimiliano Epis, Massimo Puoti
Journal of Infection, 2020
Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience
Giovanna Travi, Roberto Rossotti, Marco Merli, Alice Sacco, Giovanni Perricone, Andrea Lauterio, Valeriana G. Colombo, Luciano De Carlis, Maria Frigerio, Enrico Minetti, Luca S. Belli, Massimo Puoti
American Journal of Transplantation, 2020
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients
Valeria Cento, Luna Colagrossi, Alice Nava, Anna Lamberti, Sabrina Senatore, Giovanna Travi, Roberto Rossotti, Marta Vecchi, Ornella Casati, Elisa Matarazzo, Alessandra Bielli, Giorgia Casalicchio, Maria Antonello, Silvia Renica, Valentino Costabile, Francesco Scaglione, Roberto Fumagalli, Nicola Ughi, Oscar Massimiliano Epis, Massimo Puoti, Chiara Vismara, Marino Faccini, Diana Fanti, Claudia Alteri, Carlo Federico Perno
Journal of Infection, 2020
Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy
Enrico Ammirati, Giovanna Travi, Carloandrea Orcese, Alice Sacco, Sara Auricchio, Maria Frigerio, Massimo Puoti
Ijc Heart and Vasculature, 2020
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV
Marco Merli, Roberto Rossotti, Giovanna Travi, Fabio Ferla, Andrea Lauterio, Teresa Angelini Zucchetti, Chiara Alcantarini, Olivia Bargiacchi, Luciano De Carlis, Massimo Puoti
Transplant Infectious Disease, 2019
HIV-positive to HIV-positive liver transplantation: To be continued
Andrea Lauterio, Maria Cristina Moioli, Stefano Di Sandro, Giovanna Travi, Riccardo De Carlis, Marco Merli, Fabio Ferla, Massimo Puoti, Luciano De Carlis
Journal of Hepatology, 2019
Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage
Roberto Rossotti, Marco Merli, Marco Cantone, Maria Cristina Moioli, Davide Motta, Carloandrea Orcese, Annamaria Pazzi, Giovanna Travi, Beniamino Piero Vigo, Massimo Puoti
Infectious Diseases, 2019
Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients
Giacomo Veronese, Enrico Ammirati, Maria Cristina Moioli, Rossella Baldan, Carlo Andrea Orcese, Gisele De Rezende, Silvio Veronese, Gabriella Masciocco, Enrico Perna, Giovanna Travi, Massimo Puoti, Manlio Cipriani, Simon Tiberi, Daniela Cirillo, Maria Frigerio
Transplant Infectious Disease, 2018
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial
Massimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli, Eugenia Quiros Roldan, Alessandra Latini, Gabriella d’Ettorre, Andrea Antinori, Antonella Castagna, Giancarlo Orofino, Daniela Francisci, Pierangelo Chinello, Giordano Madeddu, Pierfrancesco Grima, Stefano Rusconi, Barbara Del Pin, Francesca Lombardi, Alessandro D’Avino, Emanuele Focà, Manuela Colafigli, Roberto Cauda, Simona Di Giambenedetto, Andrea De Luca, ATLAS-M Study Group, R Cauda, S Di Giambenedetto, M Fabbiani, A Mondi, N Ciccarelli, A Borghetti, E Baldonero, S Belmonti, A D’Avino, R Gagliardini, S Lamonica, F Lombardi, L Sidella, E Tamburrini, E Visconti, A De Luca, A Giacometti, F Barchiesi, P Castelli, O Cirioni, S Mazzocato, M Di Pietro, P Blanc, A Degli Esposti, B Del Pin, E Mariabelli, S Marini, A Poggi, E Quiros Roldan, E Focà, S Amadasi, A Apostoli, L Biasi, A Bonito, N Brianese, S Compostella, A Ferraresi, D Motta, M T Mughini, B M Celesia, M Gussio, S Sofia, P Grima, M Tana, P Tundo, C Viscoli, L De Hoffer, A Di Biagio, S Grignolo, A Parisini, E Schenone, L Taramasso, P E Manconi, A Boccone, F Ortu, P Piano, L Serusi, M Puoti, M C Moioli, R Rossotti, G Travi, F Ventura, M Galli, S Rusconi, S Di Nardo Stuppino, V Di Cristo, A Giacomelli, V Vimercati, P Viale, A Gori, G Rizzardini, A Capetti, L Carenzi, F Mazza, P Meraviglia, S Rosa, P Zucchi, M Mineo, A Latini, M Colafigli, M Giuliani, A Pacifici, F Pimpinelli, F Solivetti, F Stivali, A Antinori, F Angelici, R Bellagamba, D Delle Rose, R Fezza, R Libertone, S Mosti, P Narciso, E Nicastri, S Ottou, C Tomassi, C Vlassi, M Zaccarelli, F Zoppè, V Vullo, G D’Ettorre, F Altavilla, G Ceccarelli, A Fantauzzi, S Gebremeskel, S Lo Menzo, I Mezzaroma, F Tierno, N Petrosillo, P Chinello, E Boumis, S Cicalini, E Grilli, M Musso, C Stella, M S Mura, G Madeddu, P Bagella, M Mannazzu, V Soddu, P Caramello, G Orofino, C Carcieri, S Carosella, M Farenga, P G Scotton, M C Rossi, E Concia, F Corsini, C Gricolo, M Lanzafame, E Lattuada, S Leonardi, F Rigo, A Lazzarin, A Castagna, A Bigoloni, E Carini, S Nozza, V Spagnuolo, D Francisci, B Belfiori, L Malincarne, E Schiaroli, C Sfara, A Tosti, D Sacchini, A Ruggieri, C Valdatta
Journal of Antimicrobial Chemotherapy, 2018
Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey
David Navarro, Rafael San‐Juan, Oriol Manuel, Estela Giménez, Mario Fernández‐Ruiz, Hans H. Hirsch, Paolo Antonio Grossi, José María Aguado, ESGICH CMV Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology, Infectious Diseases (ESCMID)
Transplant Infectious Disease, 2017
Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid from Hematopoietic Stem Cell Transplant Recipients with CMV Pneumonia
Michael Boeckh, Terry Stevens-Ayers, Giovanna Travi, Meei-Li Huang, Guang-Shing Cheng, Hu Xie, Wendy Leisenring, Veronique Erard, Sachiko Seo, Louise Kimball, Lawrence Corey, Steven A Pergam, Keith R. Jerome
Journal of Infectious Diseases, 2017
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection
Giovanni Guaraldi, Roberto Rossotti, Gabriella Verucchi, Marcello Tavio, Luisa Pasulo, Barbara Beghetto, Giovanni Dolci, Giulia Nardini, Lorenzo Badia, Anna Magliano, Maria Cristina Moioli, Massimo Puoti, HIV/HCV Italian Liver Transplant Group, Giovanna Travi, Annamaria Pazzi, Luciano De Carlis, Alessandro Giacomoni, Andrea Lauterio, Iacopo Mangoni, Stefano Di Sandro, Fabio Ferla, Stefano Fagiuoli, Michele Colledan, Giuliana Cologni, Fabrizio Di Benedetto, Giuseppe Tarantino, Valentina Serra, Giovanni Dolci
Open Forum Infectious Diseases, 2017
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)
Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, Alessandra Latini, Gabriella D’Ettorre, Andrea Antinori, Antonella Castagna, Giancarlo Orofino, Daniela Francisci, Pierangelo Chinello, Giordano Madeddu, Pierfrancesco Grima, Stefano Rusconi, Massimo Di Pietro, Annalisa Mondi, Nicoletta Ciccarelli, Alberto Borghetti, Emanuele Focà, Manuela Colafigli, Andrea De Luca, Roberto Cauda, on behalf of the Atlas-M Study Group
Journal of Antimicrobial Chemotherapy, 2017
Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report
Roberto Rossotti, Giovanna Travi, Annamaria Pazzi, Chiara Baiguera, Enrica Morra, Massimo Puoti
Journal of Hepatology, 2015
Cytomegalovirus pneumonia in hematopoietic stem cell recipients
Giovanna Travi, Steven A. Pergam
Journal of Intensive Care Medicine, 2014
Optimizing treatment in HIV/HCV coinfection
Massimo Puoti, Roberto Rossotti, Giovanna Travi, Claudia Panzeri, Marco Morreale, Erika Chiari, Giorgia Cocca, Maurizio Orso, Maria Cristina Moioli
Digestive and Liver Disease, 2013
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: A matched cohort study
Vincenzo Spagnuolo, Giovanna Travi, Laura Galli, Francesca Cossarini, Monica Guffanti, Nicola Gianotti, Stefania Salpietro, Adriano Lazzarin, Antonella Castagna
Cancer, 2013
Human immunodeficiency virus and hepatitis c virus coinfection: The agenda is full while waiting for new drugs
Massimo Puoti, Maria Cristina Moioli, Roberto Rossotti, Giovanna Travi, Raffaele Bruno
Hepatology, 2013
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: A casecontrol study
Roberto Rossotti, Maria Cristina Moioli, Leonardo Chianura, Isabella Errante, Carloandrea Orcese, Maurizio Orso, Clara Schiantarelli, Irene Schlacht, Giovanna Travi, Beniamino Vigo, Maria Riccarda Villa, Alberto Volonterio, Massimo Puoti
Scandinavian Journal of Infectious Diseases, 2012
The burden of liver disease in human immunodeficiency virus-infected patients
Massimo Puoti, Maria Moioli, Giovanna Travi, Roberto Rossotti
Seminars in Liver Disease, 2012
Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies
Vincenzo Spagnuolo, Laura Galli, Stefania Salpietro, Nicola Gianotti, Monica Guffanti, Francesca Cossarini, Alba Bigoloni, Paola Cinque, Simona Bossolasco, Giovanna Travi, Luca Fumagalli, Adriano Lazzarin, Antonella Castagna
International Journal of Cancer, 2012
Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone
Giovanna Travi, Andrés J.M. Ferreri, Paola Cinque, Simonetta Gerevini, Maurilio Ponzoni, Maria Rosa Terreni, Adriano Lazzarin, Fulvio Crippa
Journal of Clinical Oncology, 2012
Top topics in HCV research arena.
Massimo Puoti, Roberto Rossotti, Giovanna Travi, Maurizio Orso, Maria Cristina Moioli
BMC Infectious Diseases, 2012
The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation
Giovanna Travi, Steven A. Pergam, Hu Xie, Paul Carpenter, Hans‐Peter Kiem, Lawrence Corey, Michael J. Boeckh
Clinical Infectious Diseases, 2009
Donor CMV Serostatus Not Predictive of Relapse in D-/R- Pediatric HCT
Giovanna Travi, Steven A. Pergam, Hu Xie, Michael J. Boeckh
Biology of Blood and Marrow Transplantation, 2009
Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection
Kehmia Titanji, Stefano Sammicheli, Angelo De Milito, Paola Mantegani, Claudio Fortis, Louise Berg, Klas Kärre, Giovanna Travi, Chiara Tassandin, Lucia Lopalco, Bence Rethi, Giuseppe Tambussi, Francesca Chiodi
Immunology, 2008

Giovanna Travi

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS